Phase 3Not yet recruiting
ACT4RHD is an Open-label, Randomised, Adaptive Platform Trial to Evaluate Novel and Repurposed Clinical Interventions for Patients With Acute Rheumatic Fever and Carditis. ACT4RHD Seeks to Determine Whether These Interventions Reduce RHD Severity at 6 Months.
ACT4RHD: Adaptive Collaborative Trial for Rheumatic Heart Disease
- Sponsor
- Starship Child Health, Te Toka Tumai Auckland (Government)
- Enrollment
- 600 planned
- Conditions
- Rheumatic Fever; Rheumatic Heart Disease in Children; Acute Rheumatic Fever; Rheumatic Heart Disease
- Interventions
- Hydroxychloroquine (HCQ); No Hydroxychloroquine (HCQ); Prednisone or Prednisolone; No corticosteroid
- Ages
- children, adults
- Registry
- NCT07830108
Full record on ClinicalTrials.gov
From the registry
The ACT4RHD trial is a multicentre, pragmatic, multi-arm, open-label adaptive platform trial addressing multiple therapeutic questions in patients with ARF and carditis. ACT4RHD aims to improve health outcomes for children and young people affected by ARF by finding treatments to reduce heart damage. The trial's Bayesian adaptive design enables multiple promising treatments to be tested at the same time. The trial will adapt by stopping treatments that are not effective sooner than traditional trials, adding new treatments as they become available, and answering research questions as soon as enough evidence has been collected. This flexibility allows researchers to identify the most effective treatments more quickly than traditional clinical trials.
Primary outcomes
- 6-point ordinal scale
History
Study completion expected
Primary completion expected
Expected to start
Last registry update
Registered